441 related articles for article (PubMed ID: 30046165)
1. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
Ghaffari A; Peterson N; Khalaj K; Vitkin N; Robinson A; Francis JA; Koti M
Br J Cancer; 2018 Aug; 119(4):440-449. PubMed ID: 30046165
[TBL] [Abstract][Full Text] [Related]
2. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
[TBL] [Abstract][Full Text] [Related]
3. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
5. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
6. Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer.
Shakfa N; Li D; Conseil G; Lightbody ED; Wilson-Sanchez J; Hamade A; Chenard S; Jawa NA; Laight BJ; Afriyie-Asante A; Tyryshkin K; Koebel M; Koti M
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37015760
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
Wan C; Keany MP; Dong H; Al-Alem LF; Pandya UM; Lazo S; Boehnke K; Lynch KN; Xu R; Zarrella DT; Gu S; Cejas P; Lim K; Long HW; Elias KM; Horowitz NS; Feltmate CM; Muto MG; Worley MJ; Berkowitz RS; Matulonis UA; Nucci MR; Crum CP; Rueda BR; Brown M; Liu XS; Hill SJ
Cancer Res; 2021 Jan; 81(1):158-173. PubMed ID: 33158814
[TBL] [Abstract][Full Text] [Related]
8. Carboplatin and programmed death-ligand 1 blockade synergistically produce a similar antitumor effect to carboplatin alone in murine ID8 ovarian cancer model.
Zhu X; Xu J; Cai H; Lang J
J Obstet Gynaecol Res; 2018 Feb; 44(2):303-311. PubMed ID: 29171115
[TBL] [Abstract][Full Text] [Related]
9. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
Shu T; Li Y; Wu X; Li B; Liu Z
Cancer Lett; 2017 Dec; 411():65-73. PubMed ID: 28989055
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity.
Walton JB; Farquharson M; Mason S; Port J; Kruspig B; Dowson S; Stevenson D; Murphy D; Matzuk M; Kim J; Coffelt S; Blyth K; McNeish IA
Sci Rep; 2017 Dec; 7(1):16827. PubMed ID: 29203787
[TBL] [Abstract][Full Text] [Related]
12. ARAP1 is an independent prognostic biomarker in older women with ovarian high-grade serous adenocarcinoma receiving first-line platinum-based antineoplastic therapy.
Nadaraja S; Schledermann D; Herrstedt J; Østrup O; Ditzel HJ;
Acta Oncol; 2020 Jan; 59(1):40-47. PubMed ID: 31478407
[No Abstract] [Full Text] [Related]
13. Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients.
Sokolenko AP; Gorodnova TV; Bizin IV; Kuligina ES; Kotiv KB; Romanko AA; Ermachenkova TI; Ivantsov AO; Preobrazhenskaya EV; Sokolova TN; Broyde RV; Imyanitov EN
Cancer Chemother Pharmacol; 2021 Sep; 88(3):439-450. PubMed ID: 34080040
[TBL] [Abstract][Full Text] [Related]
14. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
[TBL] [Abstract][Full Text] [Related]
15. Specific copy number alterations associated with docetaxel/carboplatin response in ovarian carcinomas.
Osterberg L; Levan K; Partheen K; Delle U; Olsson B; Sundfeldt K; Horvath G
Anticancer Res; 2010 Nov; 30(11):4451-8. PubMed ID: 21115892
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.
Bevis KS; McNally LR; Sellers JC; Della Manna D; Londoño Joshi A; Amm H; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2011 Apr; 121(1):193-9. PubMed ID: 21211830
[TBL] [Abstract][Full Text] [Related]
17. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
18. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
19. The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1).
Murakami R; Matsumura N; Michimae H; Tanabe H; Yunokawa M; Iwase H; Sasagawa M; Nakamura T; Tokuyama O; Takano M; Sugiyama T; Sawasaki T; Isonishi S; Takehara K; Nakai H; Okamoto A; Mandai M; Konishi I
Gynecol Oncol; 2019 May; 153(2):312-319. PubMed ID: 30853361
[TBL] [Abstract][Full Text] [Related]
20. Multi-omics in high-grade serous ovarian cancer: Biomarkers from genome to the immunome.
Clifford C; Vitkin N; Nersesian S; Reid-Schachter G; Francis JA; Koti M
Am J Reprod Immunol; 2018 Aug; 80(2):e12975. PubMed ID: 29781548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]